Judi N.A. van Diessen

ORCID: 0000-0001-9301-8530
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Lung Cancer Diagnosis and Treatment
  • Lung Cancer Treatments and Mutations
  • Radiomics and Machine Learning in Medical Imaging
  • Medical Imaging Techniques and Applications
  • Head and Neck Cancer Studies
  • Advanced Radiotherapy Techniques
  • Lung Cancer Research Studies
  • Esophageal Cancer Research and Treatment
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Cancer Diagnosis and Treatment
  • Cancer Immunotherapy and Biomarkers
  • Medical Imaging and Pathology Studies
  • Gastric Cancer Management and Outcomes
  • Cardiac tumors and thrombi
  • PI3K/AKT/mTOR signaling in cancer
  • Metabolism, Diabetes, and Cancer
  • Head and Neck Surgical Oncology
  • Multiple and Secondary Primary Cancers
  • Advances in Oncology and Radiotherapy
  • Colorectal Cancer Treatments and Studies
  • Cancer, Lipids, and Metabolism

The Netherlands Cancer Institute
2013-2025

Radiation Oncology Associates
2019

Oncode Institute
2013

Abstract Background: The phase I Induction trial (NCT04287894) assessed the feasibility and safety of induction immunotherapy (IIT) prior to concurrent chemoradiotherapy (cCRT) in patients with locally advanced non-small cell lung cancer (NSCLC). Methods: Patients unresectable stage II/III NSCLC were eligible for inclusion. received either one cycle tremelimumab (75mg) two cycles durvalumab (1500mg) cohort I, (300mg) II or III. After IIT, a comprehensive radiological pathological restaging...

10.1158/1078-0432.ccr-24-3476 article EN cc-by-nc-nd Clinical Cancer Research 2025-01-17

<p>Supplementary Figure S5: Post-IIT ADC 0-50-800 relative to baseline of matched lymph nodes (baseline pathologic sampled tumor positive also post-IIT, median 106% vs 144%, p=0.20). Abbreviations: ADC, apparent diffusion coefficient; path, pathology.</p>

10.1158/1078-0432.28606482 preprint EN cc-by 2025-03-17

<div>AbstractPurpose:<p>The phase I induction trial (NCT04287894) assessed the feasibility and safety of immunotherapy (IIT) prior to concurrent chemoradiotherapy (cCRT) in patients with locally advanced non–small cell lung cancer (NSCLC).</p>Patients Methods:<p>Patients unresectable stage II/III NSCLC were eligible for inclusion. Patients received either one cycle tremelimumab (75 mg) two cycles durvalumab (1,500 cohort I, (300 II, or III. After IIT, a comprehensive...

10.1158/1078-0432.c.7722420 preprint EN 2025-03-17

<p>Supplementary Figure S3: Post-IIT TLG of matched lymph nodes (baseline pathologic sampled tumor positive also post-IIT) (median 11.3 vs 0, p=0.04). Abbreviations: TLG, total lesion glycolysis; g, grams; path, pathology.</p>

10.1158/1078-0432.28606488 preprint EN cc-by 2025-03-17
Julianne Cynthia de Ruiter Vincent van der Noort Judi N.A. van Diessen Egbert F. Smit Ronald Damhuis and 95 more Koen J. Hartemink M.I. Amir H. van Berkum H. Bertens Manon Bindels E. Bongers R.C. Boshuizen K. de Brake-de Jong Jerry Braun Frank J.C. van den Broek Johan Bussink Sebastian Canisius Ronald Damhuis M. Deelen Jan P. Deroose C. Dickhoff Michel F.H. Dielwart Judi N.A. van Diessen M. Dubbelman-Siems Kristien Van der Elst Mohammad R. Ghamati F.A.B. Grimme M.A. de Groot Frank R. Halfwerk Koen J. Hartemink Pien Hellebrekers L.E.L. Hendriks E.R. Hendriksa S. van Heukelem A. ten Heuvel Niek Hugen Merlijn Hutteman Melek Hüyük Wouter M. IJgosse Katrien De Jaeger E.M.G.J. de Jong D. van Kampen Sven De Keersmaecker Houke M. Klomp Ewout A. Kouwenhoven Frans H. Krouwels Ernst Lammers W. B. Lastdrager K. van der Leest K. R. Liesker Elke Loos A. De Lorenzo Alexander P.W.M. Maat Jos G. Maessen Raghuveer Singh Mali N. Marquenie Geertruid M.H. Marres Burlando Martina Ilse Masselink R. Meijer David M. Mens Erik M. von Meyenfeldt Sven Michel Lars B. van Middendorp Joanna Moes-Sosnowska A. Moons-Pasic L. Morsink Johanna G. H. van Nes Marianne Van Nistelrooy Vincent van der Noort Joost J. Nuyttens J. Wolter Oosterhuis L.W.J. Oosthoek E. Osté C. Overhof-Wedick H.W. Palamba Givan F. Paulus J.W.G. van Putten S.E. van Putten Herman Rijna C.H. Rikers Julianne Cynthia de Ruiter Dirk K. De Ruysscher Mart Schiefer D.G. Schweitzer Niels Smakman E.F. Smit Wilma G.J.M. Smit Laura G. Spaans R G H Speekenbrink M E Stellingwerf Andrew J. Steward Denis Susa Eddy Van Thiel N. M. Thonissen Eelco J. Veen A.A.F.A. Veenhof A. van Velthoven-Hoogers Nathalie Verbogt Lise Verbruggen

10.1016/j.lungcan.2024.107792 article EN Lung Cancer 2024-04-12

Introduction Nasopharyngeal carcinoma (NPC) has a high incidence in Indonesia. Previous study Yogyakarta revealed complete response of 29% and median overall survival less than 2 years. These poor treatment outcome are influenced by the long diagnose-to-treatment interval to radiotherapy (DTI) extended time (OTT). This reveals insight why OTT DTI prolonged. Method All patients treated with curative intent for NPC between July 2011 until October 2012 were included. During daily diary was...

10.1371/journal.pone.0085959 article EN cc-by PLoS ONE 2014-01-23

A minimally invasive lobectomy (MIL) is the standard treatment for stage I non-small cell lung cancer (NSCLC) in medically operable patients. Stereotactic ablative radiotherapy (SABR) recommended inoperable patients and has been proposed as a potential alternative well. Here, we present results of feasibility study preparation nationwide retrospective cohort study, comparing outcomes between both modalities.In this data from with clinical NSCLC treated MIL or SABR 2014-2015 were retrieved...

10.1093/ejcts/ezac118 article EN European Journal of Cardio-Thoracic Surgery 2022-02-24

Objective: The objective of this study was to determine the volumetric change in thyroid gland nasopharyngeal carcinoma patients after undergoing chemoradiotherapy that could alter function. Furthermore, correlates mean dose effect towards decrease volume predict outcoming clinical signs radiation induced hypothyroidism (RHT). Methods: This consists a cross sectional retrospective evaluation multiplanar image comprised three planes axial, coronal, and sagittal all NPC who underwent received...

10.31557/apjcc.2024.9.4.667-672 article EN cc-by Asian Pacific Journal of Cancer Care 2024-10-16
Coming Soon ...